Variables | n | HR | 95 % CI | P value |
---|---|---|---|---|
Lung metastasis | 27 | 0.90 | 0.42–1.95 | 0.79 |
Liver metastasis | 36 | 1.25 | 0.56–2.78 | 0.59 |
Bone metastasis | 43 | 1.42 | 0.58–3.50 | 0.44 |
CNS metastasis | 9 | 1.36 | 0.44–4.17 | 0.59 |
Other metastasis | 47 | 0.46 | 0.20–1.02 | 0.06 |
Anthracycline-based regimen for EBC | 21 | 0.51 | 0.15–1.73 | 0.28 |
Anthracycline-based regimen for MBC | 24 | 0.36 | 0.11–0.83 | 0.02* |
Taxane-based regimen for EBC | 13 | 0.48 | 0.08–2.77 | 0.41 |
Taxane-based regimen for MBC | 41 | 0.66 | 0.22–1.96 | 0.45 |
Eribulin as first-/second-line for MBC | 31 | 0.90 | 0.37–2.20 | 0.82 |
Taxane-based regimen prior to eribulin | 28 | 1.41 | 0.63–3.14 | 0.40 |
Duration of eribulin treatment >median (125 days) | 33 | 0.45 | 0.21–0.94 | 0.03* |